Trevi Therapeutics (TRVI) Amortizatization of Intangibles (2022 - 2026)
Trevi Therapeutics' quarterly Amortizatization of Intangibles came in at $431000.0 in Q1 2026, up 9.11% year-on-year from $395000.0 in Q1 2025, and down 23.31% quarter-over-quarter from $562000.0 in Q4 2025.
Trevi Therapeutics has reported Amortizatization of Intangibles for 5 years, with the latest figure at $431000.0 in Q1 2026.
- For the quarter ending Q1 2026, Amortizatization of Intangibles rose 9.11% year-over-year to $431000.0; the trailing twelve-month figure through Mar 2026 stood at $1.7 million (up 127.76% YoY), and the FY2025 full-year result was $1.6 million, up 256.09% from the prior year.
- Amortizatization of Intangibles for Q1 2026 stood at $431000.0, down from $562000.0 in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $1.6 million in Q3 2023, with the low at -$1.4 million in Q4 2023.
- Average Amortizatization of Intangibles over 5 years is $244533.3, with a median of $383000.0 recorded in 2025.
- Peak annual rise in Amortizatization of Intangibles reached 4851.52% in 2023, while the deepest fall reached 291.63% in 2023.
- Tracing TRVI's Amortizatization of Intangibles over 5 years: stood at $729000.0 in 2022, then tumbled by 291.63% to -$1.4 million in 2023, then soared by 56.34% to -$610000.0 in 2024, then surged by 192.13% to $562000.0 in 2025, then declined by 23.31% to $431000.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at $431000.0 (Q1 2026), $562000.0 (Q4 2025), and $298000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13,267.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Trevi Therapeutics | 2.02 Bn | 1.85 Bn | - | 431,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 431,000.00 |
| Mar 31, 2026 | 431,000.00 |
| Dec 31, 2025 | 562,000.00 |
| Dec 31, 2025 | 562,000.00 |
| Sep 30, 2025 | 298,000.00 |
| Sep 30, 2025 | 298,000.00 |
| Jun 30, 2025 | 383,000.00 |
| Jun 30, 2025 | 383,000.00 |
| Mar 31, 2025 | 395,000.00 |
| Mar 31, 2025 | 395,000.00 |
| Dec 31, 2024 | -610,000.00 |
| Dec 31, 2024 | -610,000.00 |
| Sep 30, 2024 | 353,000.00 |
| Sep 30, 2024 | 353,000.00 |
| Jun 30, 2024 | 597,000.00 |
| Jun 30, 2024 | 597,000.00 |
| Mar 31, 2024 | 120,000.00 |
| Mar 31, 2024 | 120,000.00 |
| Dec 31, 2023 | -1.40 Mn |
| Dec 31, 2023 | -1.40 Mn |
| Sep 30, 2023 | 1.63 Mn |
| Sep 30, 2023 | 1.63 Mn |
| Jun 30, 2023 | -531,000.00 |
| Jun 30, 2023 | -531,000.00 |
| Mar 31, 2023 | 671,000.00 |
| Mar 31, 2023 | 671,000.00 |
| Dec 31, 2022 | 729,000.00 |
| Dec 31, 2022 | 729,000.00 |
| Sep 30, 2022 | 33,000.00 |
| Sep 30, 2022 | 33,000.00 |